The title of this study was modified to; "Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer" and is now partly supported by Advanced Accelerator Applications, a Novartis Company.<h4>Conclusions</h4>We present an update of the original study protocol prior to the completion of the study. Here, FOLH1 is linked to prostate cancer.